Zheng Jianyong, Li Shisen, Nie Yongzhan, Sun Hao, Wang Mian, Dai Yanran, Zhao Haihong, Pang Guanjun, Wu Guosheng, Zhao Qingchuan
Department of Digestive Surgery, Xijing Hospital of Digestive Diseases, Xijing Hospital, The Fourth Military Medical University, Xi'an 710032, China.
Zhonghua Wei Chang Wai Ke Za Zhi. 2014 Dec;17(12):1175-8.
To assess the efficacy of sacral neuromodulation (SNM) in patients with intractable constipation.
A total of 7 patients with intractable constipation were treated with pereutaneous test stimulation of the S3 nerve root and were assessed by sacral never stimulation system in our department from January 2013 to January 2014. Four of these 7 patients received operation for constipation before. The efficacy was assessed by bowel habit diary, clinic constipation scores, subjective questionnaire and clinical signs.
The constipation symptoms were improved significantly in all the 7 patients. The frequency and volume of defecation per week were increased obviously, and the average urine was increased. Six patients underwent permanent implantation of the SNS system. After a median 4 months follow-up, the defecation frequency increased from 0.6 ± 0.5 to 8.0 ± 2.5 per week (P<0.01), and the defecation time decreased from (22.9 ± 11.5) to (3.7 ± 0.8) min (P<0.01). The Cleveland clinic constipation score decreased from 24.6 ± 4.2 to 9.0 ± 0.9 (P<0.01), and the visual analogue scale(VAS) score increased from 8.1 ± 0.9 to 82.5 ± 5.2 (P<0.01).
SNM is a clinically efficacious, minimally invasive and safe new technique, which offers an alternative treatment for the patients with intractable constipation resistant to conservative treatment, especially for the patients refractory to traditional operations.
评估骶神经调节(SNM)治疗顽固性便秘患者的疗效。
2013年1月至2014年1月,我院对7例顽固性便秘患者进行了S3神经根经皮测试刺激,并采用骶神经刺激系统进行评估。这7例患者中有4例之前接受过便秘手术。通过排便习惯日记、临床便秘评分、主观问卷和临床体征评估疗效。
所有7例患者的便秘症状均有明显改善。每周排便频率和排便量明显增加,平均尿量增加。6例患者接受了SNS系统永久性植入。中位随访4个月后,排便频率从每周0.6±0.5次增加至8.0±2.5次(P<0.01),排便时间从(22.9±11.5)分钟降至(3.7±0.8)分钟(P<0.01)。克利夫兰诊所便秘评分从24.6±4.2降至9.0±0.9(P<0.01),视觉模拟量表(VAS)评分从8.1±0.9升至82.5±5.2(P<0.01)。
SNM是一种临床有效、微创且安全的新技术,为保守治疗无效的顽固性便秘患者,尤其是传统手术难治的患者提供了一种替代治疗方法。